Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease
- PMID: 20082977
- DOI: 10.1016/S1353-8020(09)70802-8
Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease
Abstract
Alpha-synuclein (alpha-syn) aggregation is central to neuropathological changes in Parkinson's disease. The aggregates spread within the central nervous system according to a very predictable pattern. A prion-like transmission of alpha-syn aggregates has been recently proposed to explain this propagation pattern. First, we review the growing evidence for such a mechanism. This process is likely to occur in three consecutive steps: (i) exit of alpha-syn template from the donor cell, (ii) entry to the recipient cell and (iii) initiation of the nucleation. In a second part, we discuss the possible underlying mechanisms for each of these steps, based on our current knowledge about how cells handle alpha-syn but also other proteins involved in neurodegenerative diseases with a prion-like propagation. Finally, we discuss which molecular species of alpha-syn (monomer, oligomer, fibril) could be the seeding-competent species and whether this seeding process could be a common mechanism in neurodegenerative diseases.
Similar articles
-
Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.Trends Mol Med. 2012 May;18(5):248-55. doi: 10.1016/j.molmed.2012.03.002. Epub 2012 Apr 13. Trends Mol Med. 2012. PMID: 22503115 Review.
-
Can Parkinson's disease pathology be propagated from one neuron to another?Prog Neurobiol. 2012 May;97(2):205-19. doi: 10.1016/j.pneurobio.2011.11.003. Epub 2011 Nov 18. Prog Neurobiol. 2012. PMID: 22115849 Review.
-
Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein.Eur J Neurosci. 2006 Dec;24(11):3153-62. doi: 10.1111/j.1460-9568.2006.05210.x. Eur J Neurosci. 2006. PMID: 17156376
-
Controlling the mass action of alpha-synuclein in Parkinson's disease.J Neurochem. 2008 Oct;107(2):303-16. doi: 10.1111/j.1471-4159.2008.05612.x. Epub 2008 Sep 2. J Neurochem. 2008. PMID: 18691382 Review.
-
Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.Brain. 2005 Nov;128(Pt 11):2654-64. doi: 10.1093/brain/awh584. Epub 2005 Jul 6. Brain. 2005. PMID: 16000336
Cited by
-
Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.Acta Neuropathol. 2014;127(6):861-79. doi: 10.1007/s00401-014-1256-4. Epub 2014 Feb 14. Acta Neuropathol. 2014. PMID: 24525765 Free PMC article.
-
A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease.Sci Rep. 2013;3:2540. doi: 10.1038/srep02540. Sci Rep. 2013. PMID: 23985836 Free PMC article.
-
Gut mucosal cells transfer α-synuclein to the vagus nerve.JCI Insight. 2023 Dec 8;8(23):e172192. doi: 10.1172/jci.insight.172192. JCI Insight. 2023. PMID: 38063197 Free PMC article.
-
Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease.Front Neurosci. 2015 Mar 9;9:59. doi: 10.3389/fnins.2015.00059. eCollection 2015. Front Neurosci. 2015. PMID: 25805964 Free PMC article. Review.
-
Plasma arylsulfatase A levels are associated with cognitive function in Parkinson's disease.Neurol Sci. 2022 Aug;43(8):4753-4759. doi: 10.1007/s10072-022-06093-w. Epub 2022 Apr 29. Neurol Sci. 2022. PMID: 35486332 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous